Tissue Regenix Group Regulatory News (TRX)

London, UK, 14 October 2015

Edison initiates coverage of Tissue Regenix

Tissue Regenix's (TRX) investment story is built on dCELL, a versatile regenerative medical technology, and its potential across the subsectors: wound care, orthopaedics and cardiac implants. We forecast that the US Wound Care subsidiary will be a driver of rapid group sales growth from the FY15 starting point of £0.1m, rising to £74m in FY21 boosted by product launches from all three divisions.

Our sum-of-the-parts DCF valuation is £325m, or 43p/share, using a 12.5% WACC. We value the wound care franchise at £175m, orthopaedics at £95m and the cardiac division at £35m. The current market capitalisation, which is subject to an estimated funding requirement of £15m needed to develop OrthoPure XT and XM in the US, does not reflect the full pipeline potential, which could ultimately be attractive to larger medtech companies.

Click here to view the full report

All reports published by Edison are available to download free of charge from its website. www.edisoninvestmentresearch.com

About Edison: We are an international equity advisory firm. We enable our client companies to achieve their capital market objectives. The team is made up of more than 80 analysts and investment professionals with many decades of experience. Our extensive company knowledge and industry expertise spans 10 business sectors and more than 700 listed companies globally. We give our corporate clients and investors privileged insight into global investment trends. Our distribution capability is key to ensuring that a global investor audience can access our investment knowledge. Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

Contact details: Learn more at www.edisongroup.com and connect with Edison on: